iRhythm Holdings, Inc. reports developments for a digital health care business focused on ambulatory cardiac monitoring and arrhythmia detection. The company’s recurring updates center on the Zio ambulatory ECG portfolio, which combines patch-based monitoring, AI-powered analysis, and clinical data review to deliver cardiac rhythm insights to physicians.
Company news commonly covers quarterly and annual financial results, revenue guidance, margin trends, and operating leverage, along with clinical evidence presented at cardiology meetings. Other updates include clinician education initiatives, investor conference participation, board and governance changes, and the company’s completed transition to a holding-company structure as successor registrant to iRhythm Technologies.
iRhythm Technologies is set to present at the 40th Annual Canaccord Genuity Global Growth Conference on August 13, 2020, at 11:30 a.m. ET in Boston, MA. The company specializes in digital health solutions for cardiac care, utilizing wearable biosensor devices and advanced cloud-based analytics for arrhythmia diagnosis. Interested participants can access the live and archived webcast through the company's website. This conference represents a significant opportunity for iRhythm to showcase its innovative approaches to cardiac health diagnostics.
iRhythm Technologies (NASDAQ: IRTC) has announced it will release its Q2 2020 financial results after market close on August 6, 2020. The management team will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can access the call via a live and archived webcast on the company’s website.
iRhythm is recognized for its innovative approach to cardiac care, utilizing wearable biosensors and cloud-based analytics to enhance arrhythmia detection.
Summary not available.